ABSTRACT
Viral or bacterial co-infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been reported in the literature. However, the knowledge on Aspergillus co-infection among patients with coronavirus disease 2019 (COVID-19) is limited. COVID‐19‐associated pulmonary aspergillosis (CAPA) has been seen in critically ill COVID-19 patients with acute respiratory distress syndrome (ARDS), which has raised concerns about the worsening disease course of COVID-19 and increasing mortality. We describe a clinical case of CAPA infection and acute respiratory distress syndrome (ARDS) with a deathly outcome in a previously well, non-immunocompromised pregnant woman with intrauterine death of the fetus. Hence, we suggest that clinicians and pathologists keep alerting the possible occurrence of pulmonary aspergillosis in severe/critical COVID-19 patients, and aggressive investigations should be done to rule out the possibility of CAPA so that early treatment can be administrated.
Keywords: COVID-19, Pulmonary Aspergillosis; Respiratory Distress Syndrome,; Fungi; SARS-CoV-2
CASE REPORT
A 20-year-old woman presented to the emergency department with generalized tonic-clonic seizures. The patient was diagnosed with disseminated intravascular coagulation (DIC), intrauterine death of the foetus (IUD), multi-organ dysfunction syndrome (MODS) and septicaemia at the 18th week of gestation. She was tested positive for coronavirus (COVID-19) by RT-PCR in a private nursing home. Her laboratory test showed hemoglobin 9.3 gm/dL (reference range [RR]; 12.0-15.0 gm/dL), total leukocyte count 22.8x109/L (RR; 4.0-11.0 x109/L), the platelet count was 108.9 x109/L (RR; 150.0-400.0 x109/L). Prothrombin time (test/control) was 24.4/11 sec, APTT 44.1/30, D-dimer 2880 ng/dL (RR; 200-500 ng/dL), fibrinogen 270 mg/dL (RR; 150-400 mg/dL), total bilirubin 4.6 mg/dL (RR; 0.3-1.2 mg/dL), direct bilirubin 2.28 mg/dL (RR;0.0-0.2 mg/dL), AST 120 U/L (RR; 0.0-35.0 U/L ), ALT 162 U/L (RR; 0.0-35.0 U/L), ALP 326.6 U/L (RR; 30.0-120.0 U/L ), GGT 16.7 U/L (RR; 0-38.0 U/L). urea 47.2 mg/dL (RR; 17.0-43.0 mg/dL), creatinine 2.81 mg/dL (RR; 0.55-1.02 mg/dL), sodium 138.1mmol/L (RR; 136-146 mmol/L) and potassium 3.96 mmol/L (RR; 3.5-5.1 mmol/L). Blood culture showed no growth after 48 hours of aerobic incubation in automated BACT/3D.
She was immediately managed symptomatically. However, the patient’s condition deteriorated despite all efforts, and she died on the second day of admission. With informed consent, the patient’s autopsy was performed under strict biosafety rules, and histopathological examination was performed (Figure 1).
Histopathological examination from the lung revealed diffuse interstitial edema along with acute and chronic inflammation (Figure 1A, B), hematoxylin and eosin). Numerous septate fungal hyphae [red arrow] with acute-angled branching were found invading blood vessels (Figure 1 C, 2AC), Grocott-Gomori's Methenamine Silver), The septate hyphae morphology was consistent with Aspergillus species (Figure 1 D and 2D).
Histopathological examination from the other organs (Kidney, Liver, Spleen, and Uterus) showed fibrin thrombi in the vessels along with the variable degree of tissue necrosis. However, they did not reveal Invasive aspergillus Infection (Figure 3 AD).
DISCUSSION
Following the recognition of coronavirus disease, 2019 (COVID-19) as a pandemic by the World Health Organisation in March 2020, COVID-19 associated-pulmonary aspergillosis (CAPA) reports are consistently being mentioned in the literature.1 - 3 Until recently, it was known that patients with acute respiratory distress syndrome due to viral infections such as influenza and SARS-CoV-2 were prone to secondary complications, especially in immunocompromised patients. Detection of aspergillosis in COVID-19 cases has been a new development wherein virus-induced severe immune dysfunction and damage to airway epithelium have been postulated to be the etiopathology for homing the fungi.4 In fact, concerns are being raised that the fungal superinfection could predispose patients with COVID-19 to a clinically worse disease contributing to the disease-associated fatality.1 , 3 We here report a case of CAPA in a young pregnant woman diagnosed with COVID-19 with no prior history of chronic immunosuppression.
Although the patient in our case had multiple contributing factors causing her mortality, it is possible that aspergillosis played a significant role in worsening the clinical scenario. The patient died despite active management with vasopressors, mechanical ventilation, and antimicrobials. A possible reason for this could be a lack of antifungal support, which would have hampered the disease progression. Furthermore, a history of IUD leading to DIC and subsequent MODS, in this case, masked the symptoms of pulmonary aspergillosis. This was compounded by normal chest X-ray findings. The possibility of nosocomial infection was excluded as the patient died the very next day of her hospitalization. Therefore, the present case emphasizes the role of autopsies for post-mortem surveillance in such a severe disease. Also, increasing availability of reports explaining the association of aspergillosis with COVID- 19 mandates screening for the fungi through non-invasive procedures such as a fungal culture or molecular studies to facilitate early detection of the fatal organism and prompt management of the disease with antifungal drugs, thereby avoiding a fatality1 , 2 , 5. Further research is necessary to evaluate the incidence of CAPA in SARS-CoV-2 infection and determine the population at risk, prophylaxis, and precise therapy.
Footnotes
How to cite: Agrawal S, Phulware RH. COVID-19 associated pulmonary aspergillosis (CAPA) in a pregnant woman. Autops Case Rep [Internet]. 2021;11:e2021313. https://doi.org/10.4322/acr.2021.313
This study was carried out at All India Institute of Medical Sciences (AIIMS). Rishikesh, Uttarakhand, India.
Ethics Statement: The authors retain informed consent signed by the deceased's next-of-kin authorizing the data publication. The manuscript publication is by the Institutional Ethics committee.
Financial support: The authors declare that no financial support was received.
REFERENCES
- 1.Koehler P, Bassetti M, Chakrabarti A, et al. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis. 2020;21(6):e149–e162. doi: 10.1016/S1473-3099(20)30847-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Nasir N, Farooqi J, Mahmood SF, Jabeen K. COVID-19-associated pulmonary aspergillosis (CAPA) in patients admitted with severe COVID-19 pneumonia: an observational study from Pakistan. Mycoses. 2020;63(8):766–770. doi: 10.1111/myc.13135. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Arkel ALE, Rijpstra TA, Belderbos HNA, Wijngaarden P, Verweij PE, Bentvelsen RG. COVID-19-associated Pulmonary Aspergillosis. Am J Respir Crit Care Med. 2020;202(1):132–135. doi: 10.1164/rccm.202004-1038LE. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020;71(15):762–768. doi: 10.1093/cid/ciaa248. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Blot SI, Taccone FS, Abeele AM, et al. A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients. Am J Respir Crit Care Med. 2012;186(1):56–64. doi: 10.1164/rccm.201111-1978OC. [DOI] [PubMed] [Google Scholar]